Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats.
Renin-angiotensin system is involved in homeostasis processes linked to renal and cardiovascular system and recently has been linked to metabolic syndrome. We analyzed the influence of long term angiotensin I converting enzyme (ACE) inhibitor enalapril treatment in normotensive adult Wistar rats fed with standard or palatable hyperlipidic diets. Our results show that long term enalapril treatment decreases absolute food intake, serum leptin concentration and body weight gain. Moreover, in adipose tissue, enalapril treatment led to decreased ACE activity, enhanced the expression of peroxisome proliferator activated receptor gamma, adiponectin, hormone-sensitive lipase, fatty acid synthase, catalase and superoxide dismutase resulting in prolonged life span. On the other hand, the ACE inhibitor was not able to improve the transport of leptin through the blood brain barrier or to alter the sensitivity of this hormone in the central nervous system. The effect of enalapril in decreasing body weight gain was also observed in older rats. In summary, these results extend our previous findings and corroborate data from the literature regarding the beneficial metabolic effects of enalapril and show for the first time that this ACE inhibitor prolongs life span in rats also fed with palatable hyperlipidic diet, an action probably correlated with adipose tissue metabolic modulation and body weight reduction.
Santos
Edson Lucas
EL
School of Environmental and Biological Science, Federal University of Grande Dourados, Rodovia dourados - Itahum, Km 12, Dourados, MS, Brazil.
de Picoli Souza
Kely
K
da Silva
Elton Dias
ED
Batista
Elice Carneiro
EC
Martins
Paulo J Forcina
PJ
D'Almeida
Vânia
V
Pesquero
João Bosco
JB
D052242:Adiponectin / Q000378:metabolism; D000273:Adipose Tissue / Q000378:metabolism; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002374:Catalase / Q000378:metabolism; D004435:Eating / Q000187:drug effects; D004656:Enalapril / Q000494:pharmacology*; D002149:Energy Intake / Q000187:drug effects; D064429:Fatty Acid Synthases / Q000378:metabolism; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008136:Longevity / Q000187:drug effects*; D008297:Male; D047495:PPAR gamma / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D002787:Sterol Esterase / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D013997:Time Factors; D015430:Weight Gain / Q000187:drug effects*
D052242:Adiponectin; D000806:Angiotensin-Converting Enzyme Inhibitors; D007328:Insulin; D020738:Leptin; D047495:PPAR gamma; D004656:Enalapril; D002374:Catalase; D013482:Superoxide Dismutase; D064429:Fatty Acid Synthases; D002787:Sterol Esterase